ANTIVIRAL ACTIVITY OF THE DRUG BASED ON THE COMPLEX OF SINGLE-STRANDED HIGH-POLYMER RNA AGAINST THE RABIES VIRUS IN VITRO

Introduction. Rabies is an infectious disease with absolute mortality. Currently, there are no effective drugs and treatment regimens for people with signs of rabies. The only strategy for post-exposure rabies prevention is vaccination and administration of rabies immunoglobulin. At the same time, the search for new treatment and prevention regimens for the disease remains relevant, which is why the development and study of antiviral drugs effective against the rabies virus is relevant. Objective of the study. To study the antiviral activity of a drug based on single-stranded high-polymer RNA of Sacharomyces cerevisiae, which has previously shown antiviral activity against other pathogens of viral infections. Material and methods. The work investigated the effect of the drug based on single-stranded high-polymer RNA of S. cerevisiae "Amphievovir" on the level of reproduction of the attenuated rabies virus strain "Saratov" on the Vero cell culture model. Results. The studied drug in the concentration range from 10 to 20 μg/ml and added to the cell culture no later than 24 hours after infection reduces the titer of the virus by 24.6 to 36.2% compared to the control group. Adding the drug to the infected cell culture later than 24 hours reduces its antiviral effect. Conclusions. The studied drug based on single-stranded high-polymer RNA of S. cerevisiae has antiviral activity against the rabies virus in vitro. The results allow us to justify further study of post-exposure rabies prophylaxis regimens using drugs based on immunostimulating and immunomodulatory RNA